Shopping Cart 0
Cart Subtotal
USD 0

Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines. The company offers ethical drugs including mucodyne, kipres, desalex, flutiform, pentasa, ketas and uritos. Its ketas product is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders. Kyorin's kipres is a bronchial asthma and allergic rhinitis therapeutic drug; and pentasa is an agent for ulcerative colitis and chrohn's disease. It offers consumer healthcare products such as milton and milton CP and OTC drugs. The company collaborates with other companies to develop new medicine. It has operations in the US and Germany. Kyorin is headquartered in Tokyo, Japan.

Kyorin Pharmaceutical Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12

Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13

MSD Enters into Distribution Agreement with Kyorin Pharma 14

MSD Enters into Agreement with Kyorin Pharma 15

Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16

Kissei Pharma Enters into Agreement with Kyorin Pharma 17

Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18

Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19

Kyorin Pharma Amends Co-Marketing Agreement with MSD 20

Eisai Enters into Agreement with Kyorin 21

Kyorin Pharma Enters Into Research Agreement With BioLeap 22

Licensing Agreements 23

Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23

Kyorin Pharma Enters into Licensing Agreement with Merck 24

Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25

Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26

Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27

R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28

Kyorin Pharma Enters into Licensing Agreement with Merck 29

Asset Transactions 30

Galderma Acquires Pekiron Cream From Kyorin Pharma 30

Kyorin Pharmaceutical Co Ltd-Key Competitors 31

Kyorin Pharmaceutical Co Ltd-Key Employees 32

Kyorin Pharmaceutical Co Ltd-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Product News 34

11/01/2017: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA 34

10/28/2017: Cleveland Clinic trial on drug shows promise in slowing progressive multiple sclerosis 35

04/25/2017: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 69th Annual Meeting in Boston 36

04/09/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois 38

02/27/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland 39

02/07/2017: MediciNova Announces MN-166 ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston 40

Clinical Trials 41

Oct 26, 2017: MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability 41

Sep 19, 2017: MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence 42

Aug 30, 2017: MediciNova Announces the Abstract from the MN-166 SPRINT-MS Phase 2b Study in Progressive MS-including Top Line Data-was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS-ACTRIMS Meeting on October 28, 2017 in Paris, France 43

Jun 05, 2017: MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting 44

Feb 06, 2017: MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research 45

Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kyorin Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12

Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13

MSD Enters into Distribution Agreement with Kyorin Pharma 14

MSD Enters into Agreement with Kyorin Pharma 15

Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16

Kissei Pharma Enters into Agreement with Kyorin Pharma 17

Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18

Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19

Kyorin Pharma Amends Co-Marketing Agreement with MSD 20

Eisai Enters into Agreement with Kyorin 21

Kyorin Pharma Enters Into Research Agreement With BioLeap 22

Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23

Kyorin Pharma Enters into Licensing Agreement with Merck 24

Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25

Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26

Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27

R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28

Kyorin Pharma Enters into Licensing Agreement with Merck 29

Galderma Acquires Pekiron Cream From Kyorin Pharma 30

Kyorin Pharmaceutical Co Ltd, Key Competitors 31

Kyorin Pharmaceutical Co Ltd, Key Employees 32

Kyorin Pharmaceutical Co Ltd, Other Locations 33

Kyorin Pharmaceutical Co Ltd, Subsidiaries 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Kyorin Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.